Geron Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,283.00
1,153.00
36,371.00
6,162.00
1,065.00
1,066
SG&A Expense
38,459.00
37,418.00
35,568.00
36,727.00
30,244.00
32,080
EBIT
37,496.00
36,312.00
747.00
30,646.00
29,255.00
31,073
Unusual Expense
1,778.00
351.00
1,290.00
-
-
919
Non Operating Income/Expense
676.00
82.00
88.00
16.00
-
154
Interest Expense
-
-
-
83.00
77.00
-
Pretax Income
38,379.00
35,670.00
46.00
29,537.00
27,916.00
27,017
Consolidated Net Income
38,379.00
35,670.00
46.00
29,537.00
27,916.00
27,017
Net Income
38,379.00
35,670.00
46.00
29,537.00
27,916.00
27,017
Net Income After Extraordinaries
38,379.00
35,670.00
46.00
29,537.00
27,916.00
27,017
Net Income Available to Common
38,379.00
35,670.00
46.00
29,537.00
27,916.00
27,017
EPS (Basic)
0.30
0.23
0.00
0.19
0.18
0.15
Basic Shares Outstanding
128,380.80
153,540.30
158,036.20
159,045.60
159,225.00
176,505
EPS (Diluted)
0.30
0.23
0.00
0.19
0.18
0.15
Diluted Shares Outstanding
128,380.80
153,540.30
162,663.90
159,045.60
159,225.00
176,505
EBITDA
37,176.00
36,265.00
803.00
30,565.00
29,179.00
31,014
Non-Operating Interest Income
219.00
373.00
677.00
1,176.00
1,416.00
3,291

About Geron

View Profile
Address
149 Commonwealth Drive
Menlo Park California 94025
United States
Employees -
Website http://www.geron.com
Updated 07/08/2019
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D.